The American College of Rheumatology (ACR) annual meeting is being held in San Francisco, CA, October 24-29, 2008. As in years past, staff from the Lupus Foundation of America are attending this meeting, to hear the latest in lupus-related research.
One of the first things to come from the meeting, that I can share with you, is in regards to epratuzumab. Study results show epratuzumab provided clinically meaningful reduced disease activity in patients with lupus. To learn more, read the press release.
As other research findings and other news from ACR become available, I will share that with you. And within the next several days, check back to read a recap of the meeting’s highlights.